Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1608P - Publication rate and characteristics of cancer clinical trials in India

Date

17 Sep 2020

Session

E-Poster Display

Topics

Bioethical Principles and GCP

Tumour Site

Presenters

Vinay Mathew Thomas

Citation

Annals of Oncology (2020) 31 (suppl_4): S903-S913. 10.1016/annonc/annonc287

Authors

V. Mathew Thomas1, V. Mathew John2, S.A. Alexander1, A.M. Roy3, A. Mathew4

Author affiliations

  • 1 Internal Medicine, UConn Health, 06030 - Farmington/US
  • 2 Radiation Oncology, Government Medical College, Thrissur, 680596 - Thrissur/IN
  • 3 Internal Medicine, University of Arkansas for Medical Sciences, 72205 - Little Rock/US
  • 4 Hematology/oncology, MOSC Medical College Kolenchery, 682311 - Kochi/IN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1608P

Background

Timely dissemination of clinical trials helps physicians provide the best possible care for patients. Non-publication of clinical trials gives rise to publication bias which distorts data available in medical literature and violates an ethical obligation to study participants. Prior research indicates that a large number of global clinical trials remain unpublished. The Clinical Trials Registry-India (CTRI) is the clinical trials registry of India. We conducted a study to determine the rate of publication of clinical trials related to cancer which were registered in CTRI and conducted in India.

Methods

We performed a cross-sectional analysis of the CTRI to determine publication rates. We searched the CTRI for completed interventional clinical trials related to cancer. A comprehensive search for publications of the registered trials was performed by three different investigators. We considered a trial to be published if the study or any outcome data pertaining to the study was accepted for publication in a peer-reviewed journal. Conference proceedings were excluded from the analysis.

Results

73 of the 133 trials (54.9%) included in our study were published. Randomized controlled trials were more likely to be published than non-randomized trials (61% vs. 34%, p 0.007). Trials funded by international pharmaceutical companies were more likely to be published than the ones by Indian pharmaceutical companies (72% vs. 24%, p < 0.00001). Trials conducted at a multinational level were more likely to be published than the ones conducted only in India (84 vs. 37%, p < 0.00001).

Conclusions

Our study reveals that a large number of cancer clinical trials remain unpublished. This could be due to reluctance on the part of the investigator to publish statistically non-significant results, and sometimes to protect intellectual property. This study reveals there is much scope for improvement in the rates of trial publication and information dissemination.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.